Implantable under the skin and capable of continuously reading glucose levels for six months without the need to change the sensor. This is the Eversense XL continuous glucose measurement sensor that is already being marketed in Spain thanks to the agreement reached with Ascensia Diabetes Care for its distribution.
Ascensia Diabetes Carea company specializing in diabetes care, has just entered the continuous glucose monitoring (CGM) marketin Europe with the distribution of Eversense XLfrom Senseonics Inc., the first and only implantable CGM in the long term of the world.
In August 2020, both companies reached a marketing and distribution agreement, whereby Ascensia can offer Eversense products to certain countries for a minimum period of 5 years. As part of said agreement, Ascensia has currently taken over distribution of Eversense XL in Germany, Switzerland, Italy, Spain, the Netherlands and Poland.
Eversense XL is the only CGM that provides continuous glucose readings for 180 daysthat is, during a period of six monthswith a single sensor that is inserted under the skin through an outpatient procedure, avoiding the user having to place a sensor every week or every fortnight.
Designed with the patient in mind, this system features a removable smart transmitter that provides discretion and tranquilitysince a system of vibration alerts The transmitter itself notifies the user if his blood glucose values are too high or low, which allows for early detection of the risk of hyper or hypoglycemia.
owns a high accuracy throughout the life of the sensor with a MARD of 9.4%. The application Eversense Mobile for monitoring and management in real time, allows users to view their data on their mobile device and share retrospective data with their healthcare professional. Furthermore, through the Eversense NOW appusers can authorize five people so they can remotely consult your readings and alerts in real time.
Rob SchummPresident of states that “Ascensia Diabetes Care’s main objective is to simplify and improve the lives of people with diabetes, entering the CGM market thanks to the alliance with Senseonics is an important step in this regard. Every person with diabetes has different needs and it is essential to cover them being able to choose the appropriate technology. Therefore, offer products eversense together with our portfolio of blood glucose meters, allows us to provide a more complete range of technologies to meet the individual needs of people with diabetes«.
For his part, Claudia GeisHead of the CGM Business Unit at Ascensia Diabetes Care explains that “we believe that an implantable CGM sensor that lasts up to 180 days is a important benefit for people with diabetesby giving them a more comfort and a better experience. The system is also known to be one of the most accurate CGMs on the market and has some unique features that offer tranquility and flexibility to users, plus discretion. Taken together, this makes Eversense a valuable technology option for healthcare professionals and people with diabetes, for monitoring information management and for better diabetes management”.